Angiotensin Metabolism

Product #

Description

Biochem/physiol Actions

Add to Cart

A4980 Abz-FRK(Dnp)P-OH trifluoroacetate salt ≥95% (HPLC), film Substrate for ACE (Angiotensin Converting Enzyme). Internally quenched fluorogenic substrate for Real Time Fluorescent Assay.
A5855 Abz-LFK(Dnp)-OH trifluoroacetate salt ≥97% (HPLC) Abz-LFK(Dnp)-OH is an Angiotensin Converting Enzyme (ACE) fluorescent peptide substrate specific for the C domain for real time fluorescent assay (ACE, Peptidyl Dipeptidase, Kininase II, E.C. 3.4.15.1).
A5730 Abz-SDK(Dnp)P-OH trifluoroacetate salt ≥91% (HPLC), lyophilized powder Abz-SDK(Dnp)P-OH is an Angiotensin Converting Enzyme (ACE) fluorescent peptide substrate specific for the N domain for real time fluorescent assay (ACE, Peptidyl Dipeptidase, Kininase II, E.C. 3.4.15.1).
5.30616 ACE2 Inhibitor, MLN-4760 ≥97% (HPLC), powder, Calbiochem® MLN-4760 is bioavailable and exhibits far greater selectivity for carboxypeptidase (IC50 = 0.44 nM against 50 pM human ACE2; [ZnCl2] = 10 μM, [MCA-APK(DNP)] = 50 μM) over bovine carboxypeptidase A or ACE peptidyldipeptidase activity (IC50 = 27 μM and >100 μM against 0.5 nM bovine CPDA and 1 nM porcine ACE, respectively; [Substrate] = 50 μM) and porcine ACE (IC50 = 27 and >100 μM, respectively). This reversible ACE2 inhibitor binds to the active site zinc with high-affinity and emulates the transition state during peptide hydrolysis. It reduces serum and kidney ACE 2 activity and abolishes angiotensin II-induced hypertension in mice. MLN-4760 selectively blocks angiotensin (ANG-(1-7)) formation in ACE2 wild type (WT) mice subjected to low ANG II concentrations (<0.1 μM), but at higher ANG II concentrations it does not affect ANG -(1-7) levels in mice. This ACE2 inhibitor enhances tumor necrosis factor (TNF) (10 pg/mL) stimulated expression of proinflammatory cytokines in murine endothelial cells, (1 μM using SVEC-40 line and primary aorta endothelial cultures) in vitro. MLN-4760 is widely employed for studying ACE2 involvement in kidney, cardiovascular and inflammatory bowel diseases via drinking water (10 mg/kg/d), i.v. (0.1 mg/kg), and s.c. (30 mg/kg/d to 300 mg/kg/12 h) injection in rats and mice, in vivo. The inhibitor leucine moiety is shown to simultaneously target ACE2 substrate S1 pocket with its isobutyl group and active site zinc via its carboxylate, while the compound′s 3,5-dichlorobenzyl group effectively occupy S1′ subsite.
MLN-4760 also enables to study the effect of reduced ACE2 activity on the lung’s susceptibility for Coronavirus disease (COVID) related acute respiratory distress syndrome (ARDS).
A2580 Angiotensin Converting Enzyme from porcine kidney lyophilized powder, ≥10 units/mg protein (Bradford) Angiotensin converting enzyme (ACE) catalyzes the conversion of angiotensin I to angiotensin II, which regulates the fluid-electrolyte balance and systemic blood pressure. ACE inhibits the vasodilator, bradykinin. ACE inhibitors are used to treat high blood pressure.
Removes C-terminal dipeptides from susceptible substrates, e.g., angiotensin I and bradykinin.
A6778 Angiotensin Converting Enzyme from rabbit lung ≥2.0 units/mg protein (modified Warburg-Christian) Removes C-terminal dipeptides from susceptible substrates, e.g., angiotensin I and bradykinin.
A0773 Angiotensin Converting Enzyme Inhibitor ≥95% (TLC)  
B0935 Benazepril hydrochloride ≥98% (HPLC), solid Benazepril is a long-acting angiotensin converting enzyme (ACE) inhibitor.
C4042 Captopril ≥98% (HPLC), powder Angiotensin converting enzyme inhibitor. Inhibits the formation of angiotensin II, a bioactive peptide that stimulates angiogenesis and increases microvessel density.
Captopril is known to decrease the cardiovascular complications arising due to myocardial infarction. It is an effective drug in treating diabetic nephropathy and renal disease. Captopril acts by reducing cardiac related inflammation, fibrosis and calcification.
E6888 Enalapril maleate salt powder, ≥98% (TLC) A long-acting angiotensin-converting enzyme inhibitor.
F1308 Fosinopril sodium ≥98% (HPLC), powder Fosinopril is an angiotensin converting enzyme (ACE) inhibitor. Fosinopril is also known to inhibit the activity of the peptide transporter PEPT2.
F7131 N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly  
H4884 Hippuryl-His-Leu acetate salt Substrate for angiotensin converting enzyme.
H1635 N-Hippuryl-His-Leu hydrate powder, ≥98% (HPLC)  
M0821 Moexipril hydrochloride powder, ≥98% (HPLC) Moexipril is an ACE-Inhibitor; Antihypertensive; Unlike other ACE inhibitors, prolongs QT interval leading to torsades de pointes and cardiad arrhythmia;
P0094 Perindopril erbumine Perindopril erbumine is an angiotensin converting enzyme (ACE) inhibitor; antihypertensive; becomes hydrolyzed in vivo to the active diacid metabolite; unlike the other ACE inhibitors, inhibits tumor growth in hepatocellular carcinoma cells due to suppression of VEGF levels; also suppresses angiotensin II production in vitro. Long-term therapy with this agent has a beneficial effect on the cerebral circulation by improving cerebral perfusion reserve in patients with previous minor stroke.
Q0632 Quinapril hydrochloride ≥98% (HPLC), solid Quinapril is a short-acting angiotensin converting enzyme (ACE) inhibitor.
R0404 Ramipril ≥98% (HPLC) Angiotensin converting enzyme (ACE) inhibitor.
T4827 Trandolapril ≥98% (HPLC), white powder Studies have reported that trandolapril inhibits atherosclerosis1 and decreases the occurrence of atrial fibrillation2.
Trandolapril is an ACE inhibitor. Trandolapril differs from other ACE inhibitors in that it has a longer biological half-life and a high degree of lipophilicity.
Z1252 Zofenopril calcium >98% (HPLC), powder Zofenopril is a long-lasting, lipophilic ACE inhibitor. Zofenopril is also an inhibitor of PEPT2, the predominant peptide transporter in kidney and choroid plexus.